ETHICS REVIEW APPROVAL

Medical Ethics Committee, The First Affiliated Hospital of Soochow University

Approval No.: (2024) Ethics Approval No. 134-1

Study Title	A Single-arm, Multi-center, Prospective Clinical Study of Mitoxantrone Hydrochloride Liposome Injection-based CMOP±R Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma		
Study Category	Clinical Research Project (Interventional Study)		
Sponsor/Initiator	Department of Hematology, The First Affiliated Hospital of Soochow University		
Principal Investigator	Haiwen Huang	**Responsible Department**	Department of Hematology
Ethics Review Reference No.	2024134 (Continuing Review 1)	**Date Accepted**	2025-04-29
Review Date	2025-05-09	**Review Category**	Research Progress Report (Scientific Research)
Reviewers	Yitao Xu, Suning Chen	**Review Method**	Expedited Review
Review Decision	In accordance with applicable Chinese laws and regulations and international ethical guidelines, the Ethics Committee conducted an expedited review of the Research Progress Report for this study. Decision: Approved to continue the study.		

Committee Chair (Signature): _____

Medical Ethics Committee, The First Affiliated Hospital of Soochow University
(Official Seal)

Date: 2025-05-09

Compliance Statement	The composition and operation of this Ethics Committee comply with GCP, applicable Chinese laws and regulations, and international ethical guidelines.

NOTICE TO THE INVESTIGATOR/SPONSOR:

1. Conduct the study in accordance with NMPA/GCP, the principles of the Declaration of Helsinki, applicable Chinese laws and regulations, and the protocol approved by the Ethics Committee, and protect the rights, interests, and safety of study subjects.
2. Before the study begins, the sponsor/investigator shall complete clinical trial registration.
3. During the study, submit amendment applications, safety reports, protocol-deviation reports, and study suspension/termination reports as required.
4. In accordance with the annual/periodic continuing review interval specified in the Ethics Committee approval, whether or not the study has begun, submit an application for continuing review and a Research Progress Report one month before the continuing review due date.
5. During the study, promptly report to the Ethics Committee any protocol deviation or modification made to eliminate an immediate hazard to study subjects; any change that increases risk to study subjects or significantly affects conduct of the clinical study; all suspected unexpected serious adverse reactions; and any new information that may adversely affect the safety of study subjects or conduct of the clinical study.
6. Upon completion of the clinical study, promptly submit the Final Study Report to the Ethics Committee for review.
7. This approval is valid for one year from the date of approval.

Ethics Committee Address and Contact Details	Address: Room 1312, Comprehensive Building, Main Campus, The First Affiliated Hospital of Soochow University, No. 899 Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China Tel.: 0512-67972861, 0512-67972743; E-mail: sdfyec@163.com

LIST OF DOCUMENTS REVIEWED

1. Research Progress Report
2. Appendix to the Research Progress Report Checklist